Publications
- Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study2022 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Cellular and humoral immune responses to SARS-CoV-2 vaccination in inflammatory bowel disease patients2022 | First Faculty of Medicine, Second Faculty of Medicine
- Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 - results from clinical practice2020 | First Faculty of Medicine
- Guidelines for the administration of biological therapy in patients with inflammatory bowel diseases: third, updated edition2016 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation2016 | First Faculty of Medicine, Second Faculty of Medicine
- Immunoexpression of type-1 adiponectin receptor in the human intestine2012 | Second Faculty of Medicine
- Sustainability of biologic treatment in paediatric patients with Crohn's disease: population-based registry analysis2024 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Tofacitinib in pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood and Breast Milk Concentrations2024 | First Faculty of Medicine, Second Faculty of Medicine
- Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?2023 | First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine
- Pulmonary tularaemia in a female adolescent with inflammatory bowel disease receiving infliximab: Do not miss the diagnosis2023 | Second Faculty of Medicine, Faculty of Medicine in Pilsen
Loading network view...